INNOVADERM CRO IS NOW INDERO.
READ THE ANNOUNCEMENT
Talk to us

Innovaderm manages a study in PPP and beats recruitment timelines

Indero

Indero

Team of Experts

Author picture

Aristea recently published Phase 2a clinical data in Dermatology and Therapy from its study managed by Innovaderm Research, highlighting the safety and potential efficacy of Aristea’s lead program RIST4721 for the treatment of moderate to severe palmoplantar pustulosis (PPP).

This study came with its challenges from Day 1:

  • It was a study being conducted in both Canada and Germany
  • On a less frequent disease indication (PPP)
  • As such, it was not easy finding trial patients that fit the necessary criteria
  • If that wasn’t challenging enough, the drug had to remain frozen, so special storage considerations had to be made for each patient’s handling

Innovaderm developed a robust recruitment strategy with multiple creative initiatives and created a strong site-patient relationship support structure with frequent site calls and follow-ups. Not only did we tackle the problems at hand, but we also beat initial recruitment timelines!

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.
Talk to us

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte prĂšs de 30 ans d’expĂ©rience dans l’industrie pharmaceutique et CRO, s’Ă©tant distinguĂ© par son leadership exceptionnel, sa vision stratĂ©gique et son innovation. L’expertise de Jeff couvre des opĂ©rations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matiĂšre de crĂ©ation de valeur, de gestion des partenaires et d’opĂ©rations CRO ont toujours contribuĂ© au succĂšs dans ses fonctions prĂ©cĂ©dentes. Sous la direction de Jeff, Indero continue d’étendre ses capacitĂ©s, faisant progresser les connaissances mĂ©dicales et les nouvelles thĂ©rapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≀3 days, and lowers costs, helping teams make informed go/no-go decisions faster.
LEARN MORE >